Skip to main content
. 2017 Dec 26;9(4):5197–5207. doi: 10.18632/oncotarget.23708

Figure 4. Therapeutic effects of promiximab and promiximab-DUBA against NCI-H526 and NCI-H69 small cell lung cancer xenografts.

Figure 4

Subcutaneous tumor-bearing mice were treated with buffer, promiximab and promiximab-DUBA at 1 mg/kg, 2.5 mg/kg, 5 mg/kg and 10 mg/kg every three days for three times. (A) Promiximab-DUBA showed more powerful inhibition of NCI-H526 subcutaneous xenografts growth compared with promiximab, even at lower dose. (B) Body weight of mice did not show significant changes during treatment for subcutaneous xenografts model. One out of two independent tumor progression experiments of the subcutaneous xenograft models had been shown. Data were presented as Mean±SEM.